Solutions like Trump’s most-favored-nation drug pricing rule risk irreparable harm to industry and patients. Pharma must save itself. Starting in the last quarter of the twentieth century, drug ...

Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare. The pharmaceutical industry is in the midst of profound ...

It happens with regularity during citizen open-mike sessions at FDA drug advisory committee hearings. A queue of “patients” materializes out of nowhere to testify, often in tears, about the crucial ...

Influenza Artificial Intelligence model build completedCytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023 LONDON, UK / ACCESSWIRE / November 29, 2022 / Poolbeg ...

ATLANTA - As the 2009 Biotechnology Industry Organization convention drew to a close, weary attendees made their final treks through the halls of the Georgia World Congress Center, catching those last ...

Model N has made further enhancements to 340B Vigilance, one of the company’s key products for pharma manufacturers to manage 340B rebates and compliance. New 340B Vigilance enhancements simplify ...

CinRx Pharma’s formula of scouting for promising drug assets and forming new companies around them has produced five “CinCos,” one of which successfully went public and went on to an acquisition by a ...